59 related articles for article (PubMed ID: 9893385)
1. Production and Purification of Filovirus Glycoproteins in Insect and Mammalian Cell Lines.
Clarke EC; Collar AL; Ye C; Caì Y; Anaya E; Rinaldi D; Martinez B; Yarborough S; Merle C; Theisen M; Wada J; Kuhn JH; Bradfute SB
Sci Rep; 2017 Nov; 7(1):15091. PubMed ID: 29118454
[TBL] [Abstract][Full Text] [Related]
2. Ebola hemorrhagic fever: Properties of the pathogen and development of vaccines and chemotherapeutic agents.
Kiselev OI; Vasin AV; Shevyryova MP; Deeva EG; Sivak KV; Egorov VV; Tsvetkov VB; Egorov AY; Romanovskaya-Romanko EA; Stepanova LA; Komissarov AB; Tsybalova LM; Ignatjev GM
Mol Biol; 2015; 49(4):480-493. PubMed ID: 32214474
[TBL] [Abstract][Full Text] [Related]
3. Clinical aspects of Marburg hemorrhagic fever.
Mehedi M; Groseth A; Feldmann H; Ebihara H
Future Virol; 2011 Sep; 6(9):1091-1106. PubMed ID: 22046196
[TBL] [Abstract][Full Text] [Related]
4. Intracellular events and cell fate in filovirus infection.
Olejnik J; Ryabchikova E; Corley RB; Mühlberger E
Viruses; 2011 Aug; 3(8):1501-31. PubMed ID: 21927676
[TBL] [Abstract][Full Text] [Related]
5. The evolving field of biodefence: therapeutic developments and diagnostics.
Burnett JC; Henchal EA; Schmaljohn AL; Bavari S
Nat Rev Drug Discov; 2005 Apr; 4(4):281-97. PubMed ID: 15803193
[TBL] [Abstract][Full Text] [Related]
6. Antibody-dependent enhancement of Ebola virus infection.
Takada A; Feldmann H; Ksiazek TG; Kawaoka Y
J Virol; 2003 Jul; 77(13):7539-44. PubMed ID: 12805454
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory responses in Ebola virus-infected patients.
Baize S; Leroy EM; Georges AJ; Georges-Courbot MC; Capron M; Bedjabaga I; Lansoud-Soukate J; Mavoungou E
Clin Exp Immunol; 2002 Apr; 128(1):163-8. PubMed ID: 11982604
[TBL] [Abstract][Full Text] [Related]
8. Infection and activation of monocytes by Marburg and Ebola viruses.
Ströher U; West E; Bugany H; Klenk HD; Schnittler HJ; Feldmann H
J Virol; 2001 Nov; 75(22):11025-33. PubMed ID: 11602743
[TBL] [Abstract][Full Text] [Related]
9. Infectivity-enhancing antibodies to Ebola virus glycoprotein.
Takada A; Watanabe S; Okazaki K; Kida H; Kawaoka Y
J Virol; 2001 Mar; 75(5):2324-30. PubMed ID: 11160735
[TBL] [Abstract][Full Text] [Related]
10. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies.
Ito H; Watanabe S; Takada A; Kawaoka Y
J Virol; 2001 Feb; 75(3):1576-80. PubMed ID: 11152533
[TBL] [Abstract][Full Text] [Related]
11. The Role of Cytokines and Chemokines in Filovirus Infection.
Bixler SL; Goff AJ
Viruses; 2015 Oct; 7(10):5489-507. PubMed ID: 26512687
[TBL] [Abstract][Full Text] [Related]
12. Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop.
Hirschberg R; Ward LA; Kilgore N; Kurnat R; Schiltz H; Albrecht MT; Christopher GW; Nuzum E
Viruses; 2014 Jul; 6(7):2673-97. PubMed ID: 25010768
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of serologic cross-reactivity using convalescent sera from filovirus-experimentally infected fruit bats.
Schuh AJ; Amman BR; Sealy TS; Flietstra TD; Guito JC; Nichol ST; Towner JS
Sci Rep; 2019 Apr; 9(1):6707. PubMed ID: 31040343
[TBL] [Abstract][Full Text] [Related]
14. Correlates of immunity to filovirus infection.
Bradfute SB; Bavari S
Viruses; 2011 Jul; 3(7):982-1000. PubMed ID: 21994766
[TBL] [Abstract][Full Text] [Related]
15. Immune response to filovirus infections.
Ignatyev GM
Curr Top Microbiol Immunol; 1999; 235():205-17. PubMed ID: 9893385
[No Abstract] [Full Text] [Related]
16. The structural basis for filovirus neutralization by monoclonal antibodies.
King LB; West BR; Schendel SL; Saphire EO
Curr Opin Immunol; 2018 Aug; 53():196-202. PubMed ID: 29940415
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
